☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - March 2020

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Cinacalcet granules (Mimpara®) have been rejected for use in secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism in adults. The manufacturer failed to make a submission for these indications. NICE recommends cinacalcet for refractory secondary hyperparathyroidism in patients with end-stage renal disease under specific conditions.

Mexiletine (Namuscla®) has been rejected for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. The justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2020' by emailShare 'SMC Update - March 2020' on FacebookShare 'SMC Update - March 2020' on TwitterShare 'SMC Update - March 2020' on LinkedInShare 'SMC Update - March 2020' on reddit


No Comments to “SMC Update - March 2020”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.